Readmission in the First Year Following Pediatric Heart Transplantation: Incidence, Indications, and Risk Factors

2019 ◽  
Vol 38 (4) ◽  
pp. S471
Author(s):  
A.N. Lambert ◽  
J.G. Weiner ◽  
M. Hall ◽  
C. Thurm ◽  
D.A. Dodd ◽  
...  
2017 ◽  
Vol 36 (4) ◽  
pp. S78 ◽  
Author(s):  
A.I. Dipchand ◽  
S. Webber ◽  
K. Much ◽  
B. Feingold ◽  
C. Bentlejewski ◽  
...  

2018 ◽  
Vol 18 (9) ◽  
pp. 2148-2162 ◽  
Author(s):  
S. Webber ◽  
A. Zeevi ◽  
K. Mason ◽  
L. Addonizio ◽  
E. Blume ◽  
...  

2019 ◽  
Vol 33 (4) ◽  
pp. e13503 ◽  
Author(s):  
Adil Mahmood ◽  
Rachel Andrews ◽  
Matthew Fenton ◽  
Alanna Morrison ◽  
Jasveer Mangat ◽  
...  

2019 ◽  
Vol 38 (4) ◽  
pp. S88-S89
Author(s):  
G. Coutance ◽  
G. Bonnet ◽  
J. Van Keer ◽  
M. Racapé ◽  
P. Bruneval ◽  
...  

2003 ◽  
Vol 22 (8) ◽  
pp. 869-875 ◽  
Author(s):  
Steven A Webber ◽  
David C Naftel ◽  
James Parker ◽  
Neda Mulla ◽  
Ian Balfour ◽  
...  

Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
Emily A Hayes ◽  
Stephen Hart ◽  
Charitha Gowda ◽  
Deipanjan Nandi

Introduction: Despite improvements in pediatric heart transplant outcomes, respiratory syncytial virus (RSV) and vaccine preventable infections (R/VPI) are a major cause of morbidity and hospital resource use. The frequency and risk factors for hospitalizations due to R/VPI in heart transplant recipients are unknown. Methods: Patients ≤18 years who underwent heart transplantation at hospitals contributing to the Pediatric Health Information System database from 9/2003 to 12/2018 were identified. The transplant hospitalization and subsequent hospitalizations for R/VPI through 12/2018 were analyzed. Risk factors for R/VPI hospitalizations were evaluated using negative regression binomial models adjusted for potential demographic and clinical confounders. Total hospital costs were determined adjusted for 2018 US $. Results: Of 3,815 transplant recipients, 681 (17.9%) had a R/VPI hospitalization during 23,746 available person-years of follow-up after transplant. There were 984 R/VPIs diagnosed during 951 hospitalizations, and 440 (44.7%) occurred in the first year after transplant (Figure). The most common causes were RSV (n=380; 38.6%), influenza (n=265; 26.9%), and pneumococcus (n=105; 10.7%). In adjusted analyses, there was an increased risk of R/VPI hospitalization in patients requiring mechanical circulatory support prior to transplant, those who received induction with ≥ 2 immunosuppressive agents, and patients <2 years old. The median length of stay for a R/VPI hospitalization was 4 days (interquartile range [IQR]: 2-8 days) with a median total cost of $11,081 (IQR: $6,215 - $24,322). Conclusions: Hospitalization for R/VPIs occurred frequently following pediatric heart transplantation and were associated with significant cost. Potential strategies to minimize R/VPI could include expanding vaccine use through accelerated immunization schedules in younger patients and routine monitoring of immunogenicity after vaccination.


Sign in / Sign up

Export Citation Format

Share Document